Nick Leschly Sells 10,823 Shares of bluebird bio, Inc. (NASDAQ:BLUE) Stock

bluebird bio, Inc. (NASDAQ:BLUE) CEO Nick Leschly sold 10,823 shares of the business’s stock in a transaction dated Tuesday, October 17th. The shares were sold at an average price of $145.05, for a total value of $1,569,876.15. Following the completion of the transaction, the chief executive officer now directly owns 262,409 shares in the company, valued at $38,062,425.45. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Nick Leschly also recently made the following trade(s):

  • On Friday, October 20th, Nick Leschly sold 3,350 shares of bluebird bio stock. The shares were sold at an average price of $145.02, for a total value of $485,817.00.
  • On Monday, October 23rd, Nick Leschly sold 7,050 shares of bluebird bio stock. The stock was sold at an average price of $145.14, for a total value of $1,023,237.00.
  • On Friday, September 1st, Nick Leschly sold 46,833 shares of bluebird bio stock. The stock was sold at an average price of $122.27, for a total value of $5,726,270.91.
  • On Wednesday, August 30th, Nick Leschly sold 25,667 shares of bluebird bio stock. The stock was sold at an average price of $115.18, for a total value of $2,956,325.06.

Shares of bluebird bio, Inc. (BLUE) traded up 3.07% during trading on Friday, reaching $140.80. The company’s stock had a trading volume of 898,715 shares. bluebird bio, Inc. has a one year low of $37.05 and a one year high of $145.70. The company’s market capitalization is $6.42 billion. The firm’s 50-day moving average price is $132.61 and its 200-day moving average price is $105.96.

bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.66) by ($0.07). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The company had revenue of $16.70 million during the quarter, compared to the consensus estimate of $6.29 million. During the same period last year, the firm posted ($1.59) EPS. The company’s revenue for the quarter was up 977.4% on a year-over-year basis. On average, equities analysts anticipate that bluebird bio, Inc. will post ($6.80) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/28/nick-leschly-sells-10823-shares-of-bluebird-bio-inc-blue-stock.html.

A number of large investors have recently bought and sold shares of the business. First Trust Advisors LP grew its position in bluebird bio by 46.9% in the 3rd quarter. First Trust Advisors LP now owns 33,043 shares of the biotechnology company’s stock worth $4,538,000 after purchasing an additional 10,552 shares during the period. Strs Ohio grew its position in bluebird bio by 20.3% in the 3rd quarter. Strs Ohio now owns 8,900 shares of the biotechnology company’s stock worth $1,222,000 after purchasing an additional 1,500 shares during the period. Winslow Evans & Crocker Inc. grew its position in bluebird bio by 31.0% in the 3rd quarter. Winslow Evans & Crocker Inc. now owns 3,800 shares of the biotechnology company’s stock worth $522,000 after purchasing an additional 900 shares during the period. Mutual of America Capital Management LLC bought a new stake in bluebird bio in the 3rd quarter worth approximately $1,264,000. Finally, Ameritas Investment Partners Inc. grew its position in bluebird bio by 5.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,600 shares of the biotechnology company’s stock worth $378,000 after purchasing an additional 191 shares during the period.

A number of research firms recently weighed in on BLUE. Cantor Fitzgerald reaffirmed a “sell” rating and set a $39.00 price target on shares of bluebird bio in a research note on Thursday, September 28th. Leerink Swann reissued an “outperform” rating and issued a $120.00 price objective on shares of bluebird bio in a research note on Saturday, September 30th. Morgan Stanley downgraded bluebird bio from an “equal weight” rating to an “underweight” rating and set a $105.00 price objective for the company. in a research note on Monday, October 2nd. Evercore ISI raised bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 price objective for the company in a research note on Monday, October 16th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $126.00 price objective on shares of bluebird bio in a research note on Wednesday, October 11th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $118.81.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply